{
  "docId": "019de076-4adb-70ab-b20d-0cecfafab920",
  "docSlug": "c241ac9edd2443452257949ce0a73d65",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 61 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 61,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The slide uses a table structure to contrast patient segments and includes a bar chart visualization for patient growth.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-4adb-70ab-b20d-0cecfafab920/20",
  "deckHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920",
  "deckJsonHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920.json",
  "deckAnchorHref": "/decks/019de076-4adb-70ab-b20d-0cecfafab920#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.8,
        "x": 0.1,
        "y": 0.67
      },
      "kind": "chart",
      "text": "Representative patient number growth",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f91fabfc-9bb4-48d9-ab97-77ccb796694f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.05,
        "y": 0.89
      },
      "kind": "paragraph",
      "text": "Recent studies of anti-BCMA BsAbs, ... demonstrate that patients may experience disease progression after treatment, leaving them with few other treatment options.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01bd56e9-20a6-432f-883d-ec109516ce2e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.02,
        "y": 0.935
      },
      "kind": "source-note",
      "text": "Source: https://doi.org/10.1038/s41591-023-02528-9 Nature Medicine, Lancet Oncol. 2020 October ; 21(10): 1317-1330. doi:10.1016/S1470-2045(20)30452-6, ; Teclistamab in Relapsed or Refractory Multiple Myeloma New England Journal of Medicine Aug 11 2022. Figures reflect cross-trial comparison and not results from a head-to head study. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies. Cohen et al 2023 https://doi.org/10.1182/blood.2022015526",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fcd9894e-f912-4c88-af84-a3bea4fb4baa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.8,
        "x": 0.1,
        "y": 0.195
      },
      "kind": "table",
      "text": "Comparison of Newly diagnosed, Standard-of-care refractory, and BCMA-exposed patient segments across treatment and results.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25bb88fb-3156-4201-8177-dd3794f3edf9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "Only CAR-T in BCMA-exposed multiple myeloma, a rapidly growing patient segment (1/2)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9fc602e-bf33-4d53-a647-9ea8d4a570e6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "d85f6da6-38b3-49a6-b04b-02aba078e8da",
      "evidence": "Comparison of Newly diagnosed, Standard-of-care refractory, and BCMA-exposed patient segments across treatment and results.",
      "confidence": 0.7
    },
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "a07d279f-6bae-4182-bcda-2e9f5ba1d3a6",
      "evidence": "table/data: Comparison of Newly diagnosed, Standard-of-care refractory, and BCMA-exposed patient segments across treatment and results.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 61,
      "from": 18,
      "beatId": "9e3b7806-5df2-416a-a768-acc5827c37ab",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "The deck concludes with a call to action, roadmap, and investment highlights",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 22,
      "from": 19,
      "name": "David Goliath",
      "slug": "16-david-goliath",
      "bestFor": "Startups, disruptive innovation, competitive displacement",
      "matchId": "4e0762bd-4e3f-4b14-9e84-63473b64f353",
      "evidence": "The deck compares NXC-201 to existing CAR-T therapies",
      "position": 1,
      "objective": "Position NXC-201 as a superior solution",
      "structure": "The Giant's Weakness -> Our Slingshot (Unique Edge) -> The Topple",
      "confidence": 0.7,
      "description": "Frame your initiative as the nimble underdog taking on a slow, bloated incumbent"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}